Mercaptopurine

Mercaptopurine is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: Mercaptopurine is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

What it is used for

Mercaptopurine is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. Acute Lymphoblastic Leukemia Mercaptopurine is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Myelosuppression
Hepatotoxicity
Immunosuppression
Treatment Related Malignancies
Macrophage Activation Syndrome

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Mercaptopurine; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/mercaptopurine
APA 7th: sofidex. (2026, August 3). Mercaptopurine. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/mercaptopurine
AMA 11th: Mercaptopurine. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/mercaptopurine

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.